| Abstract | The proven benefits of adjuvant chemotherapy on disease-free and overall survival in breast cancer can be explained by concepts of cell kill. Interventions which result in greater log kill can be expected to produce improved clinical results. The application of log-kill concepts to human breast cancer growth, which appears to follow Gompertzian kinetics, suggests not only that the use of non-cross-resistant drugs is important, but that dose-dense schedules may have an advantage over conventional schedules of drug administration. Sequential therapy may allow dose-dense administration of cytotoxic agents and encourage the integration of new biological agents into combination regimens, particularly with the taxanes. Ongoing trials in these concepts are reviewed. |
| Authors | L Norton
(Affiliation: Memorial Sloan-Kettering Cancer Center, New York, New York 10021-6007, USA. nortonl at mskcc.org)
|
| Journal | The oncologist
(Oncologist)
Vol. 6 Suppl 3
Pg. 30-5
( 2001)
ISSN: 1083-7159 United States |
| PMID | 11346683
(Publication Type: Journal Article, Review)
|
| Chemical References |
- Bridged Compounds
- Taxoids
- taxane
|
| Topics |
- Breast Neoplasms
(drug therapy)
- Bridged Compounds
(therapeutic use)
- Chemotherapy, Adjuvant
- Female
- Humans
- Taxoids
- Treatment Outcome
|
